000285036 001__ 285036
000285036 005__ 20260206170836.0
000285036 0247_ $$2doi$$a10.1080/21678421.2025.2549317
000285036 0247_ $$2pmid$$apmid:40851280
000285036 0247_ $$2ISSN$$a2167-8421
000285036 0247_ $$2ISSN$$a2167-9223
000285036 037__ $$aDZNE-2026-00161
000285036 041__ $$aEnglish
000285036 082__ $$a610
000285036 1001_ $$aTröger, Johannes$$b0
000285036 245__ $$aAutomatically measured speech intelligibility models bulbar-specific disease severity and progression in Amyotrophic Lateral Sclerosis.
000285036 260__ $$aAbingdon$$bTaylor Francis Group$$c2026
000285036 3367_ $$2DRIVER$$aarticle
000285036 3367_ $$2DataCite$$aOutput Types/Journal article
000285036 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770394038_714
000285036 3367_ $$2BibTeX$$aARTICLE
000285036 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285036 3367_ $$00$$2EndNote$$aJournal Article
000285036 520__ $$aAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that leads to widespread motor deterioration, including significant motor speech impairments. Speech intelligibility is a crucial component of communication affected in ALS, requiring objective, scalable assessment methods as an indicator of disease progression and treatment efficacy. Objective: This study investigates whether speech and bulbar function in ALS could be evaluated and monitored utilizing an automated digital measure of speech intelligibility derived from naturalistic picture descriptions. Methods: Speech recordings from 44 patients living with ALS (plwALS) and 49 matched healthy controls (HC) were analyzed and processed utilizing an automated speech analysis pipeline to extract an intelligibility score. These were part of a cross-sectional and longitudinal study involving two assessments. Results: The findings confirmed that speech intelligibility is significantly reduced in plwALS compared to HC. Those with bulbar-onset ALS have lower intelligibility than those with spinal-onset ALS, and the intelligibility of individuals with bulbar symptoms-regardless of the onset type-is lower than in plwALS without bulbar symptoms. Declining ALS-related speech scores correspond with worsening intelligibility in longitudinal assessments. Intelligibility correlates strongly with bulbar-specific clinical measures but not with global scores, highlighting its role in tracking bulbar progression. In some plwALS, we were able to demonstrate that automated speech analyses are more effective in detecting worsening in intelligibility earlier than standard clinical scoring. Conclusion: Our findings highlight that automated speech intelligibility assessments can be a valuable marker to improve clinical monitoring and facilitate earlier intervention in ALS as a supplement to standard assessments.
000285036 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285036 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285036 650_7 $$2Other$$aSpeech-based biomarkers
000285036 650_7 $$2Other$$aautomated speech analysis
000285036 650_7 $$2Other$$adisease stratification
000285036 650_7 $$2Other$$aintelligibility
000285036 650_7 $$2Other$$apatient monitoring
000285036 650_2 $$2MeSH$$aHumans
000285036 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: complications
000285036 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: physiopathology
000285036 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: diagnosis
000285036 650_2 $$2MeSH$$aMale
000285036 650_2 $$2MeSH$$aFemale
000285036 650_2 $$2MeSH$$aDisease Progression
000285036 650_2 $$2MeSH$$aMiddle Aged
000285036 650_2 $$2MeSH$$aSpeech Intelligibility: physiology
000285036 650_2 $$2MeSH$$aAged
000285036 650_2 $$2MeSH$$aCross-Sectional Studies
000285036 650_2 $$2MeSH$$aLongitudinal Studies
000285036 650_2 $$2MeSH$$aSeverity of Illness Index
000285036 650_2 $$2MeSH$$aAdult
000285036 650_2 $$2MeSH$$aSpeech Disorders: etiology
000285036 650_2 $$2MeSH$$aSpeech Disorders: diagnosis
000285036 7001_ $$aRouvalis, Andreas$$b1
000285036 7001_ $$aDörr, Felix$$b2
000285036 7001_ $$aSchwed, Louisa$$b3
000285036 7001_ $$aLinz, Nicklas$$b4
000285036 7001_ $$aKönig, Alexandra$$b5
000285036 7001_ $$0P:(DE-2719)2810317$$aMachts, Judith$$b6$$udzne
000285036 7001_ $$0P:(DE-2719)2000035$$aVielhaber, Stefan$$b7$$udzne
000285036 7001_ $$aThies, Tabea$$b8
000285036 7001_ $$0P:(DE-2719)2380559$$aPrudlo, Johannes$$b9$$udzne
000285036 7001_ $$0P:(DE-2719)2811732$$aHermann, Andreas$$b10$$udzne
000285036 7001_ $$0P:(DE-2719)9000419$$aKasper, Elisabeth$$b11$$eLast author$$udzne
000285036 773__ $$0PERI:(DE-600)2705061-0$$a10.1080/21678421.2025.2549317$$gVol. 27, no. 1-2, p. 101 - 109$$n1-2$$p101 - 109$$tAmyotrophic lateral sclerosis & frontotemporal degeneration$$v27$$x2167-8421$$y2026
000285036 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285036 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000035$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000285036 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2380559$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000285036 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000285036 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000419$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000285036 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285036 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAMYOTROPH LAT SCL FR : 2022$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000285036 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
000285036 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000285036 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x1
000285036 9201_ $$0I:(DE-2719)1511100$$kAG Hermann$$lTranslational Neurodegeneration$$x2
000285036 980__ $$ajournal
000285036 980__ $$aEDITORS
000285036 980__ $$aVDBINPRINT
000285036 980__ $$aI:(DE-2719)1510100
000285036 980__ $$aI:(DE-2719)5000006
000285036 980__ $$aI:(DE-2719)1511100
000285036 980__ $$aUNRESTRICTED